Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Elutia (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix products, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21, 2024. The company's leadership team, including Dr. Randy Mills (President and CEO), Matt Ferguson (CFO), and Dr. Michelle LeRoux Williams (Chief Scientific Officer), will be available for one-on-one meetings with institutional investors during the event. Interested institutional investors can arrange meetings through their Canaccord representatives.
Elutia (Nasdaq: ELUT), pioniere nei prodotti biomatrix a rilascio di farmaci, ha annunciato la sua partecipazione al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum a New York il 21 novembre 2024. Il team di leadership dell'azienda, incluso il Dr. Randy Mills (Presidente e CEO), Matt Ferguson (CFO) e la Dr.ssa Michelle LeRoux Williams (Chief Scientific Officer), sarà disponibile per incontri individuali con investitori istituzionali durante l'evento. Gli investitori istituzionali interessati possono organizzare incontri tramite i loro rappresentanti di Canaccord.
Elutia (Nasdaq: ELUT), pionero en productos biomatrix con liberación de fármacos, ha anunciado su participación en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum en Nueva York el 21 de noviembre de 2024. El equipo directivo de la empresa, que incluye al Dr. Randy Mills (Presidente y CEO), Matt Ferguson (CFO) y la Dra. Michelle LeRoux Williams (Directora Científica), estará disponible para reuniones individuales con inversores institucionales durante el evento. Los inversores institucionales interesados pueden coordinar reuniones a través de sus representantes de Canaccord.
Elutia (Nasdaq: ELUT)는 약물 방출 바이오매트릭스 제품의 선두주자로, 2024년 11월 21일 뉴욕에서 열리는 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum에 참가한다고 발표했습니다. 회사의 리더십 팀에는 랜디 밀스 박사(사장 겸 CEO), 맷 퍼거슨(CFO), 미셸 류로우 윌리엄스 박사(수석 과학 책임자)가 포함되며, 이벤트 동안 기관 투자자들과의 일대일 회의가 가능합니다. 관심 있는 기관 투자자는 Canaccord 대표를 통해 회의를 조정할 수 있습니다.
Elutia (Nasdaq: ELUT), pionnier dans les produits biomatrix à libération de médicaments, a annoncé sa participation au Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum à New York le 21 novembre 2024. L'équipe dirigeante de l'entreprise, y compris Dr. Randy Mills (Président et CEO), Matt Ferguson (CFO) et Dr. Michelle LeRoux Williams (Directrice scientifique), sera disponible pour des réunions individuelles avec des investisseurs institutionnels durant l'événement. Les investisseurs institutionnels intéressés peuvent organiser des réunions par l'entremise de leurs représentants Canaccord.
Elutia (Nasdaq: ELUT), ein Pionier in der Entwicklung von arzneilich beschichteten Biomatrix-Produkten, hat seine Teilnahme am Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York am 21. November 2024 bekannt gegeben. Das Führungsteam des Unternehmens, einschließlich Dr. Randy Mills (Präsident und CEO), Matt Ferguson (CFO) und Dr. Michelle LeRoux Williams (Chief Scientific Officer), wird während der Veranstaltung für Einzelgespräche mit institutionellen Investoren zur Verfügung stehen. Interessierte institutionelle Investoren können über ihre Canaccord-Vertreter Meetings anfordern.
- None.
- None.
SILVER SPRING, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a leader in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, Matt Ferguson, Chief Financial Officer, and Dr. Michelle LeRoux Williams, Chief Scientific Officer, will participate in 1x1 investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024.
Institutional investors interested in meeting with management during the conference may reach out to their Canaccord representative.
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
When is Elutia (ELUT) participating in the Canaccord Genuity Healthcare Forum?
Which Elutia (ELUT) executives are attending the Canaccord Genuity Forum in November 2024?
How can investors meet with Elutia (ELUT) management at the Canaccord Forum?
What type of meetings will Elutia (ELUT) conduct at the Canaccord Healthcare Forum?
